Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
66 studies found for:    Icotinib OR BPI-2009H
Show Display Options
Rank Status Study
1 Recruiting Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Vestibular Schwannoma;   Neurofibromatosis Type 2
Intervention: Drug: Icotinib
2 Unknown  Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
Condition: NSCLC
Intervention: Drug: Icotinib
3 Recruiting Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
Condition: Lung Cancer
Intervention: Drug: Endostar and icotinib
4 Completed Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
Conditions: Lung Cancer;   Metastatic Cancer
Intervention: Drug: Icotinib
5 Unknown  Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
Condition: NSCLC
Interventions: Drug: Icotinib of routine dose;   Drug: Icotinib of high dose
6 Not yet recruiting Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
Condition: Lung Adenocarcinoma
Interventions: Drug: Icotinib;   Drug: Pemetrexed/Carboplatin
7 Recruiting Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
Condition: Non-small Cell Lung Cancer
Intervention: Drug: icotinib
8 Active, not recruiting A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Icotinib
9 Recruiting Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Icotinib
10 Active, not recruiting First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Icotinib
11 Recruiting Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Icotinib
12 Suspended Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Icotinib
13 Recruiting The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
Condition: Non-small Cell Lung Cancer(NSCLC)
Intervention: Drug: Icotinib
14 Completed Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
Condition: Non-small Cell Lung Cancer
Intervention: Drug: icotinib
15 Recruiting Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Carcinoma
Intervention: Drug: Icotinib
16 Unknown  Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Icotinib;   Drug: Docetaxel
17 Recruiting Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy
Condition: Esophageal Squamous Cell Carcinoma
Intervention: Drug: Icotinib Hydrochloride
18 Recruiting Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Conditions: EGFR Positive Non-small Cell Lung Cancer;   Adenocarcinoma
Interventions: Drug: Sequential Icotinib Plus Chemotherapy;   Drug: Icotinib
19 Recruiting Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
Condition: Non-small-cell Lung Cancer
Intervention: Drug: Icotinib plus WBRT
20 Completed Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
Conditions: Non-small Cell Lung Cancer;   Brain Metastases
Interventions: Drug: icotinib;   Radiation: Whole brain radiotherapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.